Methods for opiate and opioid overdose prevention and reversal
AssigneeTorralva Medical Therapeutics LLC
InventorPhillip R. Torralva
Life of this patent
Estimating the term…
Abstract
Methods are described to reduce risk of or prevent wooden chest syndrome or other respiratory effects arising from exposure to fentanyl or a fentanyl analog, for instances inpatients receiving medically assisted treatment (MAT) for Opioid Use Disorder (OUD) or who are receiving analgesia and pain management with F/FAs. Pharmaceutical compositions for use in such methods are described.
Claims24
A method of preventing or reversing an opioid or opiate effect selected from respiratory depression, laryngospasm, fentanyl and fentanyl analog (F/FA) induced respiratory muscle rigidity (FIRMR), vocal cord closure (VCC), wooden chest syndrome (WCS), and unconsciousness in a subject undergoing medically assisted treatment (MAT) for Opioid Use Disorder (OUD), the method comprising administering to the subject:
- a therapeutically effective amount of at least one α1 adrenergic receptor antagonist, and
- a therapeutically effective amount of a mu or opioid subtype receptor agonist.
(canceled)
A method of preventing one or more opioid or opiate effects in a subject exposed to fentanyl or fentanyl analog(s) as part of a pain management program, comprising administering to the subject:
- a therapeutically effective amount of an α1 adrenergic receptor antagonist or mixture of two or more α1 adrenergic receptor antagonists
6-7. (canceled)
(canceled)
-24. (canceled)
A rat airway monitoring model for lead compound identification for F/FA exposure substantially as described herein.
Dependencies are inferred from the claim text.